Abstract: The present invention provides a nitroreductase-releasable pro-drug of the formula: where Ar1, m, n, Z, Y, L, and A are as defined herein, and methods for using and producing the same. Compound of formula I is useful in oral administration of the active pharmaceutical ingredient to the distal gut region of a subject to treat a wide variety of clinical conditions associated with distal gut region of a subject, such as colorectal cancer, inflammatory bowel disease (IBD), infectious diarrhea, bacterial infections, and bacterial overgrowth.

Abstract: Disclosed are anti-cancer compounds and imaging agents. More specifically, the disclosed agents target carbonic anhydrase IX and XII and their use in the treatment of cancer, in particular breast cancer. Specific compounds are those that have Formula II wherein R1 and R2 are each independently chosen from (CH2)nC?CH and, L is a linking moiety; n is 1-8; m is 0-8; each X is independently chosen from R3, OR3, NH2, NHR3, and; and each R3 is independently chosen from a detectable moiety or targeting moiety, with the proviso that R1 and R2 are not both (CH2)4C?CH.

Abstract: Disclosed is CT or MR contrast agent which comprises a base or carrier scaffold formed of a polyhydroxol compound having a linker to which a Gd-DOTA is covalently bonded. Also disclosed is a method of screening a patient for colon cancer using a CT or MR contrast, which method comprises administering to a patient undergoing screening a compound as above described.

Abstract: The present invention provides a process for nitrating aromatic compounds without the need for a solid catalyst and/or any organic solvents and/or any other additives. A typical process includes combining or admixing a nitric acid and an anhydride compound under conditions sufficient to produce a reactive intermediate. The aromatic compound to be nitrated is then added to this reactive intermediate to produce a nitroaromatic compound. The nitroaromatic compound can be substituted with one or more, typically, one to three, and often one or two nitrate (—NO2) groups.

Abstract: The present invention provides a process for nitrating aromatic compounds without the need for a solid catalyst and/or any organic solvents and/or any other additives. A typical process includes combining or admixing a nitric acid and an anhydride compound under conditions sufficient to produce a reactive intermediate. The aromatic compound to be nitrated is then added to this reactive intermediate to produce a nitroaromatic compound. The nitroaromatic compound can be substituted with one or more, typically, one to three, and often one or two nitrate (—NO2) groups.

Abstract: Disclosed is CT or MR contrast agent which comprises a base or carrier scaffold formed of a polyhydroxol compound having a linker to which a Gd-DOTA is covalently bonded. Also disclosed is a method of screening a patient for colon cancer using a CT or MR contrast, which method comprises administering to a patient undergoing screening a compound as above described.

Abstract: The present invention provides a composition comprising a disaccharide where at least one of the hydroxyl groups of the disaccharide is attached to a linker. The terminal portion of the linker also includes a drug that is attached via a functional group that is capable of releasing the drug in vivo. Compositions of the invention are useful for delivering the drug at or near inter alia lower GI tract. In some embodiments, compositions of the invention are used for, but not limited to, treating diseases of the colon, and in particular, inflammatory bowel disease, microscopic colitis, and eosinophilic colitis.

Abstract: A composition and method for targeted delivery of substances to the lower GI tract comprises a base or scaffold carrier to which a drug or prodrug is fixed or covalently attached. Compound, when taken orally travels through the GI tract of a patient to the lower GI where bacterial azo reductace enzymes cleave the bonds, releasing the drug or prodrug from the base or scaffold carrier permitting the delivery of the drug to the vicinity of a target cell type in the GI tract. The base or scaffold, which remains as a by-product passes out of the GI tract in the feces.

Abstract: Pleckstrin homology domain binding compounds, pharmaceutical compositions including such compounds, and methods for their use are described herein.

Abstract: Pleckstrin homology domain binding compounds, pharmaceutical compositions including such compounds, and methods for their use are described herein.

Abstract: Pleckstrin homology domain binding compounds, pharmaceutical compositions including such compounds, and methods for their use are described herein.

Abstract: Pleckstrin homology domain binding compounds, pharmaceutical compositions including such compounds, and methods for their use are described herein.

Abstract: Pleckstrin homology domain binding compounds, pharmaceutical compositions including such compounds, and methods for their use are described herein.

Abstract: Biomodulators, which regulate cellular differentiation and proliferation, as well as methods of use thereof, e.g., for treating various conditions, e.g., cancer, senescence, immunological disorders and vascular disease; for stimulating normal tissue architecture after injury; for vaccination; for stimulating the production of biologically important molecules by cells or organs in culture; for maintaining organs or tissues outside of a body after removal from the body and prior to transplantation; and for producing of vascular grafts for transplantation; are provided.

Abstract: Biomodulators, which regulate cellular differentiation and proliferation, as well as methods of use thereof, e.g., for treating various conditions, e.g., cancer, senescence, immunological disorders and vascular disease; for stimulating normal tissue architecture after injury; for vaccination; for stimulating the production of biologically important molecules by cells or organs in culture; for maintaining organs or tissues outside of a body after removal from the body and prior to transplantation; and for producing of vascular grafts for transplantation; are provided.